While not fully approved, the company has early access available to people who meet the treatment criteria and would potentially benefit. Their HCP should evaluate this (it's not all types of pancreatic cancer, and it's not a silver bullet - but it looks like its double the survival time than current chemo). Hopefully this evolves into a new class of treatment.